EN
关于我们
ABOUT US
Position:
Homepage
/
About Vcare

Company Profile

ABOUT US

Jiangsu Vcare PharmaTech Co. Ltd., located in Nanjing Jiangbei New Area, one of state-level new areas, is a high-tech company providing research and development services for the whole industry chain of chemical drugs. Vcare specializes in R&D, application and domestic/international transfer of generic and innovative drugs and R&D, manufacture and sales of featured pharmaceutical intermediates.

Vcare was founded by professors of China Pharmaceutical University and overseas returnees in August 2010. Now Vcare has 350 researchers including 9 doctors and 92 masters. The whole team have many years of industry background and strong technological advantages in chemical synthesis and generic and innovative drug development, and has extensive experience in business management.

Vcare has 21,000m2 comprehensive R&D center located at No. 136, Huakang Road, Jiangbei New Area, Nanjing as well as several cooperative manufacturing bases and is honored as National High-Tech Enterprise, Nanjing Chemical Drug Engineering Technology Research Center, Jiangbei New Area Lingque Enterprise and co-built a provincial graduate workstation with China Pharmaceutical University. Vcare takes the international advanced management mode to operate well-equipped laboratories for synthesis, analysis, formulation, cell and enzyme activity detection and has an experienced clinical audit management team. Vcare can provide clients with "chemical + pharmaceutical + clinical" full-industry chain development services based on well-developed research and development system, quality management system and production conditions.

Vcare has formed innovative drug, generic drug and pharmaceutical intermediate pipelines mainly focusing on cardiac-cerebral vascular, tumor and endocrine areas. Up to now, Vcare has applied 5 INDs and 20 ANDAs and assisted clients with obtaining 9 clinical trial approvals and 8 production licenses. Vcare’s IND Vicagrel has successively obtained “Twelfth Five-Year Plan” and “Thirteenth Five-Year Plan” national major support. There are dozens featured generics intermediate projects under manufacturing in Vcare’s cooperative bases. Vcare has accumulatively applied 89 domestic and international patents and 21 patents have been authorized.

威凯尔
  • 12 year

    Professional R&D

  • 89 +

    Invention patent applications at home and abroad

  • 350 +

    Existing employees

  • 21000

    Enterprise R&D and production area

Development History

2021.2

2021

In 2021 Round A financing of 200 million yuan was completed.
2020.12

2020

In December, phase I clinical trial of vc004 project was launched
2020.10

2020

In 2020 and October, the company relocated a new site.
2019.6

2019

In June 2019, the phase II clinical trial of Vecagrelor was completed.
2018.5

2018

In May 2018, a phase II clinical trial of Vecagrelor was initiated.
2017.8

2017

In August, the recruitment, shooting and hanging of land for R & D headquarters in Nanjing Hi-tech Industrial Development Zone was completed.
2017.5

2017

In May and May 2017, the merger and acquisition of Nantong API Factory was completed.
2017.1

2017

In January 2017, the phase I clinical trial of Viagra was completed
2015.6

2015

In June, the phase I clinical trial of Viagra was started
2015.3

2015

In March 2015, with a valuation of 250 million yuan and a financing of 150 million yuan, it became an enterprise under the top 500 Yatai Group in China. In June 2015, it initiated the phase I clinical trial of Vicagrelor. In January, the phase I clinical trial of Vicagrelor was completed.
2014.2

2014

In February 2014, Vicat gray submitted a clinical application
2011

2011

In 2011, the Class 1.1 new drug Vicagrelor project was launched.
2010.8

2010

In 2010, in August, the company was established and currently has a registered capital of 35.4452 million yuan.

Qualifications

Honor

2011

In 2011, the company was rated as a private science and technology enterprise in Jiangsu Province; it was funded by the Technology Innovation Fund for Small and Medium-sized Scientific and Technological Enterprises of the Ministry of Science and Technology

2013

He was awarded the title of high-tech enterprise and small and medium-sized scientific and technological enterprise in Jiangsu Province in 2013 

2016

Established Nanjing Engineering Research and Technology Center in 2016; received funding from Jiangsu Key R & D Program (Social Development) project 

2017

In 2017, he was selected as an enterprise under the "Lantern Program" in Jiangbei New Area and established a graduate workstation for provincial enterprises; he was funded by the National "Thirteenth Five-Year Plan" Major Project 

2018

He won the third prize of Jiangsu Provincial Science and Technology Award and established the Academician Workstation of Jiangsu Enterprise in 2018

2019

In 2019, Nanjing Postdoctoral Innovation Practice Base, Southern Jiangsu National Independent Innovation Demonstration Zone and Jiangsu Provincial R & D enterprises were established to obtain the special funds for the transformation of scientific and technological achievements in Jiangsu Province 

2020

In 2020, it was recognized as the first batch of municipal headquarters enterprises in Nanjing in 2020, Nanjing Stunning Enterprise, Nanjing Research Center for Pharmaceutical Chemical Engineering, selected as the cultivation bank of innovative leading enterprises in Nanjing, and won the Science and Technology Innovation Award of Jiangbei New Area in Nanjing 

这是描述信息

Contact Us

Add:No. 136, Huakang Road, Jiangbei New Area, Nanjing, P. R. China

这是描述信息

Scan to see

Copyright © Jiangsu Vcare PharmaTech Co. Ltd.,

苏ICP备17050189号-1        Powerby:300.cn

中兴能源